Roth Capital Issues Pessimistic Forecast for TRDA Earnings

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Equities researchers at Roth Capital decreased their Q3 2025 earnings per share (EPS) estimates for Entrada Therapeutics in a report released on Wednesday, August 6th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will earn ($1.13) per share for the quarter, down from their previous estimate of ($0.97). The consensus estimate for Entrada Therapeutics’ current full-year earnings is $1.12 per share. Roth Capital also issued estimates for Entrada Therapeutics’ Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($3.86) EPS, Q1 2026 earnings at ($1.32) EPS, Q2 2026 earnings at ($1.38) EPS, Q3 2026 earnings at ($1.45) EPS, Q4 2026 earnings at ($1.51) EPS and FY2026 earnings at ($5.66) EPS.

TRDA has been the subject of several other reports. Wall Street Zen downgraded Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Tuesday, May 20th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.67.

Entrada Therapeutics Trading Down 2.1%

TRDA stock opened at $5.19 on Monday. The company has a market capitalization of $197.43 million, a P/E ratio of -2.92 and a beta of -0.12. Entrada Therapeutics has a twelve month low of $4.98 and a twelve month high of $21.79. The business has a 50 day simple moving average of $6.90 and a 200-day simple moving average of $8.96.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.18). The firm had revenue of $1.98 million during the quarter, compared to analyst estimates of $8.17 million. Entrada Therapeutics had a negative net margin of 92.30% and a negative return on equity of 17.81%.

Institutional Investors Weigh In On Entrada Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC lifted its holdings in Entrada Therapeutics by 21.6% in the fourth quarter. Janus Henderson Group PLC now owns 2,080,367 shares of the company’s stock valued at $36,011,000 after acquiring an additional 368,908 shares during the period. Merck & Co. Inc. acquired a new stake in Entrada Therapeutics in the first quarter valued at $15,728,000. Vanguard Group Inc. lifted its holdings in Entrada Therapeutics by 19.7% in the fourth quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company’s stock valued at $25,317,000 after acquiring an additional 241,052 shares during the period. Wellington Management Group LLP lifted its holdings in Entrada Therapeutics by 2.1% in the first quarter. Wellington Management Group LLP now owns 1,053,314 shares of the company’s stock valued at $9,522,000 after acquiring an additional 21,488 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Entrada Therapeutics by 7.2% in the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after acquiring an additional 42,479 shares during the period. Institutional investors and hedge funds own 86.39% of the company’s stock.

Insider Buying and Selling at Entrada Therapeutics

In related news, Director Kush Parmar sold 27,000 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total transaction of $202,500.00. Following the completion of the sale, the director directly owned 1,093,313 shares of the company’s stock, valued at $8,199,847.50. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ventures V. L.P. 5Am sold 6,935 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total value of $52,012.50. Following the sale, the insider directly owned 1,093,313 shares of the company’s stock, valued at approximately $8,199,847.50. This represents a 0.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 254,000 shares of company stock valued at $1,782,000. Corporate insiders own 7.59% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.